A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
~56 mi.
(Nizhniy Novgorod,
Russia,
+144 more cities)
Nizhniy Novgorod Region Oncology Dispensary ( Site 2621)
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
~56 mi.
(Nizhniy Novgorod,
Russia,
+176 more cities)
Nizhegorodsky Regional Oncology Dispensary-chemotherapy department (Branch№1) ( Site 2639)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
~56 mi.
(Nizhniy Novgorod,
Russia,
+89 more cities)
Nizhegorodsky Regional Oncology Dispensary-chemotherapy ( Site 1912)
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
~56 mi.
(Nizhniy Novgorod,
Russia,
+383 more cities)
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
~56 mi.
(Nizhniy Novgorod,
Russia,
+159 more cities)
Volga District Medical Center Federal Medical and Biological Agency ( Site 0857)
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
~56 mi.
(Nizhniy Novgorod,
Russia,
+163 more cities)
Volga District Medical Center Federal Medical and Biological Agency ( Site 0857)
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
~56 mi.
(Nizhniy Novgorod,
Russia,
+158 more cities)
Nizhniy Novgorod Region Oncology Dispensary ( Site 1914)
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
~56 mi.
(Nizhniy Novgorod,
Russia,
+260 more cities)
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)
~56 mi.
(Nizhniy Novgorod,
Russia,
+93 more cities)
Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0809)
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
~56 mi.
(Nizhniy Novgorod,
Russia,
+122 more cities)
Nizhniy Novgorod Region Oncology Dispensary ( Site 1811)
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
~56 mi.
(Nizhniy Novgorod,
Russia,
+137 more cities)
Nizhniy Novgorod regional clinical oncological dispensary ( Site 1169)